株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

癌のDNA損傷応答 (DDR) 薬:分析ツール

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool

発行 BioSeeker Group AB 商品コード 755823
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.62円で換算しております。
Back to Top
癌のDNA損傷応答 (DDR) 薬:分析ツール DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool
出版日: 2018年12月05日 ページ情報: 英文
概要

DNA損傷応答 (DDR) は細胞のゲノム的完全性を維持するために必須の機能であり、その破壊が癌の特徴のひとつとされています。通常細胞への影響を最小限に抑えながら癌細胞を優先的に死滅させるためのDDR欠損への標的化は、癌生存率を高める、より選択的でより忍容性が高い治療薬となる可能性を秘めています。

当ツールは、癌のDNA損傷応答 (DDR) 薬の開発に携わる399社を超える企業とそのパートナーによる最新の動向をまとめたもので、835種の治療薬 (うち412件が226種の標的を対象とし癌治療薬として積極的な開発段階) に関する各種データをオンラインアクセスにて提供しています。

提供内容

  • 分析ツール
    • 1年間のオンラインアクセス
    • 内容・特集の隔週アップデート
    • パイプラインアラート
    • オンラインサポート
    • データ内容
      • 各種契約・提携
      • 新技術・薬剤
      • 資金調達・助成金・IPO
      • 申請・承認
      • 最新の臨床試験動向・結果
      • 新たに開始された臨床試験
      • 主要学会の情報
        • AACR
        • ASCO
        • ASGCT
        • ASH
        • CIMT
        • EHA
        • EORTC-NCI-AACR
        • ESMO
        • SITC
        • BIO (世界・欧州・アジア)
      • バイオマーカー/コンパニオン診断薬の開発
      • 併用療法の選択肢
      • 適応症の選定・拡大
      • ドラッグリポジショニングの機会、など
目次
Product Code: BSG21819

DNA Damage Response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer. Targeting DDR deficiencies to preferentially kill cancer cells, while minimizing the impact on normal cells, has potential for more selective, better tolerated therapies to improve survival in multiple cancers.

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your DDR drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool achieves this by continuously scanning development in DDR and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool covers more than 399 companies plus partners who are today developing 835 DDR drugs where of 412 are in active development in cancer across 226 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top